https://www.selleckchem.com/products/blu-451.html
001). The median overall survival was 65.7 months (range 2.9-108.6), the median progression free survival was 17.4 months (range 2.7-70. and local tumor control was achieved in 96.7% of patients. Adverse events were limited to 8.3% of patients, with one grade 4 toxicity within 6 weeks after RRS therapy. RRS is a safe and effective treatment option in selected patients with metastatic RCC in a multimodal approach. Further research is warranted to confirm our findings prospectively.This paper presents an open-source environment for deve